製品の概要

製品の詳細

  • 由来Synthetic

関連製品

特性

Our Abpromise guarantee covers the use of ab37304 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • アプリケーション

    Blocking - Blocking peptide for Anti-BCL9 antibody (ab37305)

    Western blot

  • 製品の状態Liquid
  • 備考

    - First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions.
    - If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer.
    - Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent.
    - Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised.
    - Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use.

  • Concentration information loading...

前処理および保存

  • 保存方法および安定性

    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

    Information available upon request.

関連情報

  • 別名
    • B-cell CLL/lymphoma 9
    • BCL 9
    • Legless homolog
    • LGS
  • 関連性BCL9 is involved in signal transduction through the Wnt pathway. It promotes beta-catenin's transcriptional activity. BCL9 is associated with B-cell acute lymphoblastic leukemia. The overexpression of BCL9 may be of pathogenic significance in B-cell malignancies (referenced from swissprot and entrez gene).
  • 細胞内局在Nuclear

Human BCL9 peptide 画像

  • BCL9 staining in Human colorectal cancer tissue, blocked with ab37304.

    Left panel: ab37305 - BCL9 antibody alone. Right panel: BCL9 antibody + ab37304 - BCL9 peptide.

Human BCL9 peptide (ab37304) 使用論文

This product has been referenced in:
  • Takada K  et al. Targeted disruption of the BCL9/ß-catenin complex inhibits oncogenic Wnt signaling. Sci Transl Med 4:148ra117 (2012). Blocking ; Human . Read more (PubMed: 22914623) »
  • Mani M  et al. BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Res 69:7577-86 (2009). WB . Read more (PubMed: 19738061) »

See all 2 Publications for this product

Product Wall

There are currently no Abreviews or Questions for ab37304.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"